NASDAQ:ALDX - Aldeyra Therapeutics Stock Price, Forecast & News

Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) released its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.55) by $0.14. View Aldeyra Therapeutics' Earnings History.

Aldeyra Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 13th 2020. View Earnings Estimates for Aldeyra Therapeutics.

3 brokerages have issued 12 month price targets for Aldeyra Therapeutics' shares. Their forecasts range from $20.00 to $38.00. On average, they expect Aldeyra Therapeutics' stock price to reach $30.33 in the next twelve months. This suggests a possible upside of 465.9% from the stock's current price. View Analyst Price Targets for Aldeyra Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aldeyra Therapeutics.

Media stories about ALDX stock have been trending negative recently, InfoTrie reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aldeyra Therapeutics earned a media sentiment score of -2.6 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an effect on the company's share price in the next several days. View News Stories for Aldeyra Therapeutics.

Aldeyra Therapeutics saw a drop in short interest in November. As of November 29th, there was short interest totalling 570,900 shares, a drop of 5.3% from the November 14th total of 602,900 shares. Based on an average trading volume of 304,600 shares, the short-interest ratio is presently 1.9 days. Currently, 2.4% of the shares of the company are short sold. View Aldeyra Therapeutics' Current Options Chain.

Some companies that are related to Aldeyra Therapeutics include Retrophin (RTRX), Magenta Therapeutics (MGTA), Cytokinetics (CYTK), Phathom Pharmaceuticals (PHAT), Provention Bio (PRVB), Viking Therapeutics (VKTX), Dermira (DERM), Crinetics Pharmaceuticals (CRNX), RAPT Therapeutics (RAPT), Lexicon Pharmaceuticals (LXRX), Prothena (PRTA), Morphic (MORF), Stemline Therapeutics (STML), Emisphere Technologies (EMIS) and Frequency Therapeutics (FREQ).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), TherapeuticsMD (TXMD), Abeona Therapeutics (ABEO), AVEO Pharmaceuticals (AVEO), Catabasis Pharmaceuticals (CATB), Micron Technology (MU), Corbus Pharmaceuticals (CRBP), Aimmune Therapeutics (AIMT) and NVIDIA (NVDA).

Aldeyra Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (1.91%), Hikari Power Ltd (0.29%), Squarepoint Ops LLC (0.22%), Russell Investments Group Ltd. (0.21%), Strs Ohio (0.11%) and Stifel Financial Corp (0.09%). Company insiders that own Aldeyra Therapeutics stock include Ben Bronstein, David Mcmullin, Jesse I Treu, Joshua Reed, Richard Douglas and Todd C Brady. View Institutional Ownership Trends for Aldeyra Therapeutics.

ALDX stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Squarepoint Ops LLC, Strs Ohio, Stifel Financial Corp and Barclays PLC. View Insider Buying and Selling for Aldeyra Therapeutics.

ALDX stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Hikari Power Ltd and Meeder Asset Management Inc.. Company insiders that have bought Aldeyra Therapeutics stock in the last two years include Ben Bronstein, David Mcmullin, Joshua Reed, Richard Douglas and Todd C Brady. View Insider Buying and Selling for Aldeyra Therapeutics.

Shares of ALDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALDX stock can currently be purchased for approximately $5.36.

Aldeyra Therapeutics has a market capitalization of $149.83 million. The biotechnology company earns $-38,890,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. View Additional Information About Aldeyra Therapeutics.

The official website for Aldeyra Therapeutics is http://www.ampliphibio.com/.

Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-761-4904 or via email at [email protected]